• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDY
Click for more information
1.43% 7.1¢

CELLMID LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
CDY Trading HaltPRICE SENSITIVE11/12/14
CDY Cellmid signs agreement with ZoetisPRICE SENSITIVE17/11/14
CDY Appendix 4C - quarterlyPRICE SENSITIVE29/10/14
CDY Appendix 4E and Preliminary Final ReportPRICE SENSITIVE29/08/14
CDY Appendix 4C - quarterlyPRICE SENSITIVE29/07/14
CDY Cellmid Granted UK Patent for Use of Midkine for Hair GrowthPRICE SENSITIVE16/07/14
CDY Landmark Study- FGF5 Critical Regulator of Human Hair GrowthPRICE SENSITIVE15/07/14
CDY Quest Diagnostic License UpdatePRICE SENSITIVE20/06/14
CDY Manufacturing Partner Appointed by CellmidPRICE SENSITIVE19/06/14
CDYKey Milestone Completed, Lead Antibody SelectedPRICE SENSITIVE07/05/14
CDYSignificant New Findings Presented at 3rd Midkine SymposiumPRICE SENSITIVE30/04/14
CDYAppendix 4C - quarterlyPRICE SENSITIVE28/04/14
CDYAppendix 4D and Half Yearly AccountsPRICE SENSITIVE27/02/14
CDYUSA RNA/DNA Patent for Surgical Adhesion AllowedPRICE SENSITIVE10/02/14
CDYChinese Distribution Agreement Signed for Hair Loss ProductsPRICE SENSITIVE29/01/14
CDYAppendix 4C - quarterlyPRICE SENSITIVE28/01/14
CDYResults of Completed CK3000 Diagnostic StudyPRICE SENSITIVE18/12/13
CDYCapital Raising of $2 millionPRICE SENSITIVE11/12/13
CDYTrading HaltPRICE SENSITIVE09/12/13
CDYAppendix 4C - quarterlyPRICE SENSITIVE23/10/13
CDYKey Antibody Patent Granted in JapanPRICE SENSITIVE18/10/13
CDYKey European Patent for Anti-Midkine Antibodies GrantedPRICE SENSITIVE08/10/13
CDYR&D Tax Refund ReceivedPRICE SENSITIVE04/10/13
CDYMidkine antibodies effective in cancerPRICE SENSITIVE03/10/13
CDYCellmid Signs Major Japanese Distribution AgreementPRICE SENSITIVE20/09/13
CDYAppendix 4E and Preliminary Final ReportPRICE SENSITIVE28/08/13
CDYCellmid Received Pacific Edge Milestone SharesPRICE SENSITIVE01/08/13
CDYCellmid Collaborates on Early Diagnosis of Colorectal CancerPRICE SENSITIVE29/07/13
CDYAppendix 4C - quarterlyPRICE SENSITIVE26/07/13
CDYFujikura Exercises Option To License Cellmid DiagnosticsPRICE SENSITIVE18/07/13
CDYAdvangen AcquisitionPRICE SENSITIVE08/05/13
CDYTrading HaltPRICE SENSITIVE06/05/13
CDYAppendix 4C - quarterlyPRICE SENSITIVE22/04/13
CDYCellmid Diagnostic Licenses UpdatePRICE SENSITIVE26/03/13
CDYCellmid Completes $2M PlacementPRICE SENSITIVE13/03/13
CDYTrading HaltPRICE SENSITIVE11/03/13
CDYResponse to ASX Price QueryPRICE SENSITIVE08/03/13
CDYResponse to ASX Price QueryPRICE SENSITIVE27/02/13
CDYAppendix 4D and Half Year AccountsPRICE SENSITIVE15/02/13
CDYCellmid Signs Midkine Diagnostic AgreementPRICE SENSITIVE11/02/13
CDYAppendix 4C - quarterlyPRICE SENSITIVE29/01/13
CDYPositive Data in Midkine Antibody Study in Kidney DiseasePRICE SENSITIVE23/01/13
CDYResponse to ASX Aware QueryPRICE SENSITIVE22/01/13
CDYEU Patent Allowed for Treating Vascular Occlusive DiseasePRICE SENSITIVE21/01/13
CDYAppendix 4C - quarterlyPRICE SENSITIVE22/10/12
CDY$748K R&D Tax Credit ReceivedPRICE SENSITIVE02/10/12
CDYUnderwritten Non-Renounceable Pro-Rata Offer and PlacementPRICE SENSITIVE14/09/12
CDYEvolis Hair Growth Products Exceed Distribution TargetsPRICE SENSITIVE13/09/12
CDYExclusive Distributor Appointed for evolisPRICE SENSITIVE04/09/12
CDYAppendix 4E and Preliminary Final ReportPRICE SENSITIVE30/08/12
CDYResponse to ASX QueryPRICE SENSITIVE27/07/12
CDYMidkine Ischemia Patent Allowed in USPRICE SENSITIVE26/07/12
CDYAppendix 4C - quarterlyPRICE SENSITIVE23/07/12
CDYEvolis to be Sold in Terry White Chemist OutletsPRICE SENSITIVE30/05/12
CDYTreg Antibody Patent Allowed in USAPRICE SENSITIVE07/05/12
CDYAppendix 4C - quarterlyPRICE SENSITIVE26/04/12
CDYCellmid Completes $1.5M PlacementPRICE SENSITIVE24/04/12
CDYTrading HaltPRICE SENSITIVE23/04/12
CDYUSA Antibody Patent for Adhesion AllowedPRICE SENSITIVE18/04/12
CDYMedia Launch of Evolis Hair ProductsPRICE SENSITIVE29/03/12
CDYAnnual Report on Celera (Quest) LicensePRICE SENSITIVE05/03/12
CDYAppendix 4D and Half Year AccountsPRICE SENSITIVE28/02/12
CDYTGA Registration and Launch of Cellmid's Evolis ProductsPRICE SENSITIVE15/02/12
CDYLa Jolla Cove Funding Agreement TerminatedPRICE SENSITIVE13/02/12
CDYAppendix 4C - quarterlyPRICE SENSITIVE30/01/12
CDYCompleted Midkine Study for Normal Reference RangePRICE SENSITIVE01/12/11
CDYRights Issue and Placement of ShortfallPRICE SENSITIVE29/11/11
CDYUS Patent for the Prevention or Treatment of IschemiaPRICE SENSITIVE14/11/11
CDYAppendix 4C - quarterlyPRICE SENSITIVE31/10/11
CDYNon-Renounceable Rights IssuePRICE SENSITIVE26/10/11
CDYCE Marking of Cellmid's Midkine ELISAPRICE SENSITIVE12/10/11
CDYCompleted Humanisation of First Ever Anti-midkine AntibodyPRICE SENSITIVE06/10/11
CDYAppendix 4E and Preliminary Final ReportPRICE SENSITIVE29/08/11
CDYCompleted GMP Manufacture of Midkine TestPRICE SENSITIVE02/08/11
CDYAppendix 4C - quarterlyPRICE SENSITIVE25/07/11
CDYCelera License UpdatePRICE SENSITIVE25/05/11
CDYAppendix 4C - quarterlyPRICE SENSITIVE19/04/11
CDYCellmid Signs Antibody Humanisation CollaborationPRICE SENSITIVE13/04/11
CDYCompletion of Proof of Concept Study for Heart AttackPRICE SENSITIVE11/04/11
CDYUpdate on Cellmid's Japanese OperationsPRICE SENSITIVE16/03/11
CDYAppendix 4D and Half Year AccountsPRICE SENSITIVE22/02/11
CDYCellmid Launches Midkine Blood TestPRICE SENSITIVE03/11/10
CDYFirst Quarter Activities ReportPRICE SENSITIVE28/10/10
CDYCellmid Secures US$8M FundingPRICE SENSITIVE15/09/10
CDYPreliminary Final ReportPRICE SENSITIVE27/08/10
CDYPreclinical Study Shows Reduction in Disease SeverityPRICE SENSITIVE19/08/10
CDYAppendix 4C - quarterlyPRICE SENSITIVE28/07/10
CDYCellmid and Pacific Edge Sign Cancer Diagnostic LicensePRICE SENSITIVE19/05/10
CDYJoint Research Agreement Signed with Kumamoto UniversityPRICE SENSITIVE21/04/10
CDYAppendix 4C - quarterlyPRICE SENSITIVE21/04/10
CDYNew midkine results for heart attack treatmentPRICE SENSITIVE12/04/10
CDYCDY Signs Collaboration for Heart Attack TreatmentPRICE SENSITIVE03/03/10
CDYHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
CDYAppendix 4C - quarterlyPRICE SENSITIVE29/01/10
CDYResponse to ASX Price QueryPRICE SENSITIVE15/01/10
CDY$3.63 Million Capital Raising CompletedPRICE SENSITIVE26/11/09
CDYTrading HaltPRICE SENSITIVE24/11/09
CDY Trading Halt
11/12/14PRICE SENSITIVE
CDY Cellmid signs agreement with Zoetis
17/11/14PRICE SENSITIVE
CDY Appendix 4C - quarterly
29/10/14PRICE SENSITIVE
CDY Appendix 4E and Preliminary Final Report
29/08/14PRICE SENSITIVE
CDY Appendix 4C - quarterly
29/07/14PRICE SENSITIVE
CDY Cellmid Granted UK Patent for Use of Midkine for Hair Growth
16/07/14PRICE SENSITIVE
CDY Landmark Study- FGF5 Critical Regulator of Human Hair Growth
15/07/14PRICE SENSITIVE
CDY Quest Diagnostic License Update
20/06/14PRICE SENSITIVE
CDY Manufacturing Partner Appointed by Cellmid
19/06/14PRICE SENSITIVE
CDYKey Milestone Completed, Lead Antibody Selected
07/05/14PRICE SENSITIVE
CDYSignificant New Findings Presented at 3rd Midkine Symposium
30/04/14PRICE SENSITIVE
CDYAppendix 4C - quarterly
28/04/14PRICE SENSITIVE
CDYAppendix 4D and Half Yearly Accounts
27/02/14PRICE SENSITIVE
CDYUSA RNA/DNA Patent for Surgical Adhesion Allowed
10/02/14PRICE SENSITIVE
CDYChinese Distribution Agreement Signed for Hair Loss Products
29/01/14PRICE SENSITIVE
CDYAppendix 4C - quarterly
28/01/14PRICE SENSITIVE
CDYResults of Completed CK3000 Diagnostic Study
18/12/13PRICE SENSITIVE
CDYCapital Raising of $2 million
11/12/13PRICE SENSITIVE
CDYTrading Halt
09/12/13PRICE SENSITIVE
CDYAppendix 4C - quarterly
23/10/13PRICE SENSITIVE
CDYKey Antibody Patent Granted in Japan
18/10/13PRICE SENSITIVE
CDYKey European Patent for Anti-Midkine Antibodies Granted
08/10/13PRICE SENSITIVE
CDYR&D Tax Refund Received
04/10/13PRICE SENSITIVE
CDYMidkine antibodies effective in cancer
03/10/13PRICE SENSITIVE
CDYCellmid Signs Major Japanese Distribution Agreement
20/09/13PRICE SENSITIVE
CDYAppendix 4E and Preliminary Final Report
28/08/13PRICE SENSITIVE
CDYCellmid Received Pacific Edge Milestone Shares
01/08/13PRICE SENSITIVE
CDYCellmid Collaborates on Early Diagnosis of Colorectal Cancer
29/07/13PRICE SENSITIVE
CDYAppendix 4C - quarterly
26/07/13PRICE SENSITIVE
CDYFujikura Exercises Option To License Cellmid Diagnostics
18/07/13PRICE SENSITIVE
CDYAdvangen Acquisition
08/05/13PRICE SENSITIVE
CDYTrading Halt
06/05/13PRICE SENSITIVE
CDYAppendix 4C - quarterly
22/04/13PRICE SENSITIVE
CDYCellmid Diagnostic Licenses Update
26/03/13PRICE SENSITIVE
CDYCellmid Completes $2M Placement
13/03/13PRICE SENSITIVE
CDYTrading Halt
11/03/13PRICE SENSITIVE
CDYResponse to ASX Price Query
08/03/13PRICE SENSITIVE
CDYResponse to ASX Price Query
27/02/13PRICE SENSITIVE
CDYAppendix 4D and Half Year Accounts
15/02/13PRICE SENSITIVE
CDYCellmid Signs Midkine Diagnostic Agreement
11/02/13PRICE SENSITIVE
CDYAppendix 4C - quarterly
29/01/13PRICE SENSITIVE
CDYPositive Data in Midkine Antibody Study in Kidney Disease
23/01/13PRICE SENSITIVE
CDYResponse to ASX Aware Query
22/01/13PRICE SENSITIVE
CDYEU Patent Allowed for Treating Vascular Occlusive Disease
21/01/13PRICE SENSITIVE
CDYAppendix 4C - quarterly
22/10/12PRICE SENSITIVE
CDY$748K R&D Tax Credit Received
02/10/12PRICE SENSITIVE
CDYUnderwritten Non-Renounceable Pro-Rata Offer and Placement
14/09/12PRICE SENSITIVE
CDYEvolis Hair Growth Products Exceed Distribution Targets
13/09/12PRICE SENSITIVE
CDYExclusive Distributor Appointed for evolis
04/09/12PRICE SENSITIVE
CDYAppendix 4E and Preliminary Final Report
30/08/12PRICE SENSITIVE
CDYResponse to ASX Query
27/07/12PRICE SENSITIVE
CDYMidkine Ischemia Patent Allowed in US
26/07/12PRICE SENSITIVE
CDYAppendix 4C - quarterly
23/07/12PRICE SENSITIVE
CDYEvolis to be Sold in Terry White Chemist Outlets
30/05/12PRICE SENSITIVE
CDYTreg Antibody Patent Allowed in USA
07/05/12PRICE SENSITIVE
CDYAppendix 4C - quarterly
26/04/12PRICE SENSITIVE
CDYCellmid Completes $1.5M Placement
24/04/12PRICE SENSITIVE
CDYTrading Halt
23/04/12PRICE SENSITIVE
CDYUSA Antibody Patent for Adhesion Allowed
18/04/12PRICE SENSITIVE
CDYMedia Launch of Evolis Hair Products
29/03/12PRICE SENSITIVE
CDYAnnual Report on Celera (Quest) License
05/03/12PRICE SENSITIVE
CDYAppendix 4D and Half Year Accounts
28/02/12PRICE SENSITIVE
CDYTGA Registration and Launch of Cellmid's Evolis Products
15/02/12PRICE SENSITIVE
CDYLa Jolla Cove Funding Agreement Terminated
13/02/12PRICE SENSITIVE
CDYAppendix 4C - quarterly
30/01/12PRICE SENSITIVE
CDYCompleted Midkine Study for Normal Reference Range
01/12/11PRICE SENSITIVE
CDYRights Issue and Placement of Shortfall
29/11/11PRICE SENSITIVE
CDYUS Patent for the Prevention or Treatment of Ischemia
14/11/11PRICE SENSITIVE
CDYAppendix 4C - quarterly
31/10/11PRICE SENSITIVE
CDYNon-Renounceable Rights Issue
26/10/11PRICE SENSITIVE
CDYCE Marking of Cellmid's Midkine ELISA
12/10/11PRICE SENSITIVE
CDYCompleted Humanisation of First Ever Anti-midkine Antibody
06/10/11PRICE SENSITIVE
CDYAppendix 4E and Preliminary Final Report
29/08/11PRICE SENSITIVE
CDYCompleted GMP Manufacture of Midkine Test
02/08/11PRICE SENSITIVE
CDYAppendix 4C - quarterly
25/07/11PRICE SENSITIVE
CDYCelera License Update
25/05/11PRICE SENSITIVE
CDYAppendix 4C - quarterly
19/04/11PRICE SENSITIVE
CDYCellmid Signs Antibody Humanisation Collaboration
13/04/11PRICE SENSITIVE
CDYCompletion of Proof of Concept Study for Heart Attack
11/04/11PRICE SENSITIVE
CDYUpdate on Cellmid's Japanese Operations
16/03/11PRICE SENSITIVE
CDYAppendix 4D and Half Year Accounts
22/02/11PRICE SENSITIVE
CDYCellmid Launches Midkine Blood Test
03/11/10PRICE SENSITIVE
CDYFirst Quarter Activities Report
28/10/10PRICE SENSITIVE
CDYCellmid Secures US$8M Funding
15/09/10PRICE SENSITIVE
CDYPreliminary Final Report
27/08/10PRICE SENSITIVE
CDYPreclinical Study Shows Reduction in Disease Severity
19/08/10PRICE SENSITIVE
CDYAppendix 4C - quarterly
28/07/10PRICE SENSITIVE
CDYCellmid and Pacific Edge Sign Cancer Diagnostic License
19/05/10PRICE SENSITIVE
CDYJoint Research Agreement Signed with Kumamoto University
21/04/10PRICE SENSITIVE
CDYAppendix 4C - quarterly
21/04/10PRICE SENSITIVE
CDYNew midkine results for heart attack treatment
12/04/10PRICE SENSITIVE
CDYCDY Signs Collaboration for Heart Attack Treatment
03/03/10PRICE SENSITIVE
CDYHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
CDYAppendix 4C - quarterly
29/01/10PRICE SENSITIVE
CDYResponse to ASX Price Query
15/01/10PRICE SENSITIVE
CDY$3.63 Million Capital Raising Completed
26/11/09PRICE SENSITIVE
CDYTrading Halt
24/11/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip Wealth Within chief analyst Dale Gillham and senior analyst Fil Tortevski have tipped $4.68 billion garbage giant Cleanaway Waste Management Limited (ASX:CWY) as their Hotcopper Hot Stock tip of the week @ especially because it seems to be slowly building towards a euphoric run akin to its mid 20...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.